论文部分内容阅读
目的：在动物实验的基础上，我们将ＯＰＴ－ｍｓ进行临床研究。材料和方法：选择２６例原发性肝癌采用粒径为１５４μｍ－２００μｍ，用量１５０ｍｇ－４００ｍｇ：如微球加ＭＭＣ（２０ｍｇ）进行肝动脉灌注，平均２．６次。通过观察血清中ＡＦＰ的下降和肿瘤在ＣＴ上最大层面的两相互垂直的最大径的乘积的改变判定其临床效果，可进行了粗略地随访。结果：９３．３％的病人（１４／１５）ＡＦＰ下降在５０％以下。治疗后肿瘤缩小大于５０％者１２例占４６．６％；缩小在２５％－５０％（ＭＲ）７例占２６．９％；缩小（ＰＲ）小于２５％（ＮＣ）５例占２０％；２例增大（ＰＤ）占７．７％。所有治疗的病人临床症状得以好转和生活质量提高，生存期明显延长，全身副作用仅是一过性的。结论：初步临床应用表明：ＯＰＴ－ｍｓ对于ＰＬＣ肝动脉栓塞化疗效果是明显的，是一种良好未梢栓塞剂。
Objective: Based on animal experiments, we will conduct clinical studies of OPT-ms. Materials and Methods: Twenty-six patients with primary liver cancer were selected to have a particle size of 154 μm-200 μm and a dose of 150 mg-400 mg: if the microspheres plus MMC (20 mg) were used for hepatic artery perfusion, an average of 2.6 times. A cursory follow-up can be made by observing the decrease in serum AFP and the change in the product of the tumor’s maximal dimension of the tumor’s two largest vertical dimensions. RESULTS: In 93.3% of patients (14/15) AFP fell below 50%. After treatment, tumor shrinkage was more than 50% in 12 cases (46.6%); in 25%-50% (MR), 7 cases accounted for 26.9%; reduced (PR) was less than 25% (NC) in 5 cases in 20%; Two cases increased (PD) accounted for 7.7%. All patients treated had improved clinical symptoms and improved quality of life. The survival time was significantly longer and the systemic side effects were only transient. Conclusion: The preliminary clinical application shows that OPT-ms is effective for PLC hepatic artery embolization chemotherapy and is a good tipping embolic agent.